Journal of clinical oncology : official journal of the American Society of Clinical Oncology
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, Ederson Roberto de Mattos, Ki-Seong Eom, Alexander Egle, Anna Panovska, Zhanet Grudeva Popova, Hsuan-Jen Shih, Luis Felipe Casado Montero, Paolo Sportoletti, Vu Minh Hua, James T D'Olimpio, Shinsuke Iida, Rodrigo Ito
Published: 202510.1200/JCO-25-02380
Abstract
PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a co…
Preview only. Read the full abstract at the source